No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients

AIDS Research and Human Retroviruses

Volumn 21, Issue 12, 2005, Pages 991-996

  Vrisekoop, Nienke ^a,b   Sankatsing, Sanjay U C ^c,d   Jansen, Christine A ^a   Roos, Marijke Th L ^a   Otto, Sigrid A ^a,b   Schuitemaker, Hanneke ^a   Lange, Joep M A ^c,d   Prins, Jan M ^c   Miedema, Frank ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d International Antiviral Therapy Evaluation Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; KI 67 ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; BLOOD CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS IMMUNITY; VIRUS REPLICATION; ACUTE DISEASE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ACUTE DISEASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 30344488130     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.991     Document Type: Article

References (44)

1. Chun T-W, Finzi D, Margolick J, et al.: In vivo fate of HIV-1 infected cells: Quantitative analysis of the transition to stable latency. Nat Med 1995;1:1284-1290.
2. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
3. Chun T-W, Stuyver L, Mizzel SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
4. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
5. Havlir DV, Strain MC, Clerici M, et al.: Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003;77(20):11212-11219.
6. Ramratnam B, Mittler JE, Zhang L, et al.: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000;6:82-85.
7. Zhang L, Ramratnam B, Tenner-Racz K, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340(21):1605-1613.
8. Dornadula G, Zhang H, VanUitert B, et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-1632.
9. Lewin SR, Vesanen M, Kostrikis L, et al.: Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999;73(7):6099-6103.
10. Furtado MR, Callaway DS, Phair JP, et al.: Persistance of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340(21):1614-1622.
11. Cohen Stuart JW, Hazenberg MD, Hamann D, et al.: The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000;25(3):203-211.
12. Allison AC and Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118.
13. Allison AC and Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
14. Eugui EM, Almquist SJ, Muller CD, and Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33(2):161-173.
15. Quemeneur L, Flacher M, Gerland LM, et al.: Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002;169(5):2747-2755.
16. Laliberte J, Yee A, Xiong Y, and Mitchell BS: Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood 1998;91(8):2896-2904.
17. Ichimura H and Levy JA: Polymerase substrate depletion: A novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211(2):554-560.
18. Margolis D, Heredia A, Gaywee J, et al.: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;21(5):362-370.
19. Chapuis AG, Paolo RG, D'Agostino C, et al.: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000;6(7):762-768.
20. Sankatsing SU, Jurriaans S, van Swieten P, et al.: Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004;18(14):1925-1931.
21. Sankatsing SU, Hoggard PG, Huitema AD, et al.: Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 2004;43(12):823-832.
22. Roos MThL, Prins M, Koot M, et al.: Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS 1998;12(14):1745-1751.
23. Hazenberg MD, Cohen Stuart JWT, Otto SA, et al.: T cell division in human immunodeficiency virus (HIV-1)-infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active anti-retroviral therapy. Blood 2000;95(1):249-255.
24. Garcia F, Plana M, Arnedo M, et al.: Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: A randomized pilot study. J Acquir Immune Defic Syndr 2004;36(3):823-830.
25. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
26. Jurriaans S, Sankatsing SUC, Prins JM, et al.: HIV-1 seroreversion after HAART in a HIV-1 seropositive immunocompetent patient. AIDS 2004;18(11):1607- 1608.
27. Hellerstein MK, Hoh RA, Hanley MB, et al.: Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 2003;112(6):956-966.
28. Pakker NG, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998;4(2):208-214.
29. - T-cell subset contains specialized primed cells. J Immunol 1995;154:17-25.
30. + T cells. J Exp Med 1997;186(9):1407-1418.
31. Coull JJ, Turner D, Melby T, et al.: A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001;26(5):423-434.
32. Press N, Kimel G, Harris M, et al.: Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens. HIV Clin Trials 2002;3(1):17-20.
33. Carr SF, Papp E, Wu JC, and Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268(36):27286-27290.
34. Fairbanks LD, Bofill M, Ruckemann K, and Simmonds HA: Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995;270(50):29682-29689.
35. Cowan MJ, Fraga M, and Ammann AJ: Changes in purine nucleoside phosphorylase activity during thymosin-induced human null cell differentiation. Cell Immunol 1983;78(2):333-341.
36. Cohen A, Lee JW, Dosch HM, and Gelfand EW: The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. J Immunol 1980;125(4):1578-1582.
37. Izeradjene K and Revillard JP: Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 2001;71(1):118-125.
38. Jansen CA, Kostense S, Vandenberghe K, et al.: High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B 57 in HIV-infection. Eur J Immunol 2005;35(1):150-158.
39. Jansen CA, De Cuyper IM, Steingrover R, et al.: Analysis of the effect of HAART during acute HIV-1 infection on HIV-specific CD4+ T-cell functions. AIDS 2005;19(11):1145-1154.
40. van Baarle D, Hovenkamp E, Callan MF, et al.: Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001;98(1):146-155.
41. de Lathouder S, Gerards AH, De Groot ER, Valkhof M, and Aarden LA: Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. Eur Cytokine Netw 2002;13(3):317-323.
42. Izeradjene K, Quemeneur L, Michallet MC, Bonnefoy-Berard N, and Revillard JP: Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc 2001;33(3):2110-2111.
43. Tambussi G, Rizzardi GP, Lazzarin A, and Pantaleo G: Patterns of viral rebound and CD4 slopes in patients with primary HIV-1 infection with persistent undetectable viremia treated with supervised treatment interruption plus mycophenolate mofetil. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
44. Rizzardi GP, Guaraldi G, Lazzarin A, Pantaleo G, and Tambussi G: Long-term control of HIV-1 RNA replication following a unique supervised treatment interruption and mycophenolate mofetil therapy in patients treated with HAART since primary HIV-1 infection. Presented at the 11th Conference on Retroviruses and Opportunistic infections, San Francisco, CA, 2004.